The CEI tracked seven cardiometabolic factors, including body weight, waist circumference, HbA1c, systolic blood pressure, triglycerides, HDL cholesterol, and LDL cholesterol.

A US study suggests GLP-1 therapies could be personalized beyond obesity by adjusting dosage or drug type to optimize cardiometabolic outcomes.

Across evaluated therapies, placebo-adjusted weight reductions averaged at least 10 percent of body weight.

In a meta-analysis of 19 randomized trials totaling 13,117 participants, researchers introduced the CEI to evaluate cardiometabolic health across these seven measures.

Senior author notes there may not be a single universally best GLP-1 therapy; treatment should be tailored to individual goals and needs.

Researchers analyzed data from more than 13,000 overweight participants across trials using the Cardiometabolic Efficacy Index (CEI) to measure improvements in body weight, waist circumference, HbA1c, blood pressure, and lipid levels.

Researchers advocate a comprehensive, personalized approach when selecting GLP-1 therapies for patients.

Higher-dosage GLP-1 agonists showed greater cardiometabolic gains, with a 7.2 mg semaglutide achieving the highest CEI score among comparators.

In metabolic effects, orforglipron led in blood sugar control, HDL cholesterol, and systolic blood pressure, while semaglutide had the strongest impact on LDL cholesterol, total body weight, and waist circumference.

Semaglutide at 7.2 mg delivered the top CEI; notable results also seen with orforglipron at 36 mg and semaglutide at 2.4 mg across different domains.

Future priorities include focusing obesity treatment on overall health and broader cardiometabolic outcomes, developing multidimensional tools like CEI for personalization, and expanding access with oral GLP-1 therapies.

The study, published in Diabetes, Obesity, and Metabolism, draws on trials and analyses from leading U.S. medical institutions.